洛铂与顺铂联合氟尿嘧啶介入治疗胃肠道肿瘤肝转移的价值

Objective To explore the clinical application value of lobaplatin combined with 5-fluorouracil(5-FU) versus cisplatin combined with 5-FU in the interventional treatment of liver metastasis of gastrointestinal tumors. Methods Seventy patients with gastrointestinal tumors accompanied by liver metastasis from January 2024 to October 2025 were selected and randomly divided into two groups of 35 each using a random number table method. The control group received 5-FU combined with cisplatin treatment, while the observation group received lobaplatin combined with 5-FU treatment. The therapeutic effects of the two groups were compared. Results The disease control rate and world health organization quality of life short form(WHOQOL-BREF) score of the observation group after treatment were higher than those of the control group, and the levels of serum tumor markers, visual analog scale(VAS) score, brief fatigue inventory(BFI) score, and incidence of adverse reactions were lower than those of the control group(P<0.05). Conclusion In the interventional treatment of gastrointestinal tumor liver metastasis, the lobaplatin combined with 5-FU regimen can improve the disease control rate of patients, reduce the levels of serum tumor markers, alleviate pain and fatigue, enhance quality of life, and reduce the occurrence of adverse reactions, which was superior to the cisplatin combined with 5-FU regimen.